149 related articles for article (PubMed ID: 14751839)
1. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
Holmlund JT
Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
3. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
4. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
Stewart A
Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
[No Abstract] [Full Text] [Related]
5. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides in lung cancer.
Pujol JL; Jacot W
Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
[No Abstract] [Full Text] [Related]
7. Antisense approaches in drug discovery and development.
Rayburn E; Wang W; Zhang R; Wang H
Prog Drug Res; 2005; 63():227-74. PubMed ID: 16265883
[No Abstract] [Full Text] [Related]
8. Antisense strategies targeting protein kinase C: preclinical and clinical development.
Tortora G; Ciardiello F
Semin Oncol; 2003 Aug; 30(4 Suppl 10):26-31. PubMed ID: 12917818
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
10. Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen.
Lahn M; Sundell K; Moore S
Ann N Y Acad Sci; 2003 Dec; 1002():263-70. PubMed ID: 14751841
[TBL] [Abstract][Full Text] [Related]
11. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes.
Nestle FO; Mitra RS; Bennett CF; Chan H; Nickoloff BJ
J Invest Dermatol; 1994 Oct; 103(4):569-75. PubMed ID: 7930684
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
McKay RA; Miraglia LJ; Cummins LL; Owens SR; Sasmor H; Dean NM
J Biol Chem; 1999 Jan; 274(3):1715-22. PubMed ID: 9880552
[TBL] [Abstract][Full Text] [Related]
13. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells.
Dai DJ; Lu CD; Lai RY; Guo JM; Meng H; Chen WS; Gu J
World J Gastroenterol; 2005 Jan; 11(2):193-9. PubMed ID: 15633214
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition effect of liposomes survivin antisense oligonucleotide on human gastric carcinoma transplanted subcutaneously in nude mice].
Fu G; Wang GB; Lu XM; Yang C
Zhonghua Wai Ke Za Zhi; 2004 Nov; 42(22):1367-71. PubMed ID: 15634406
[TBL] [Abstract][Full Text] [Related]
16. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis.
Coma S; Noe V; Lavarino C; Adán J; Rivas M; López-Matas M; Pagan R; Mitjans F; Vilaró S; Piulats J; Ciudad CJ
Oligonucleotides; 2004; 14(2):100-13. PubMed ID: 15294074
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
18. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
19. Antisense knockdown of PKC-alpha using LNA-oligos.
Hansen JB; Westergaard M; Thrue CA; Giwercman B; Oerum H
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1607-9. PubMed ID: 14565477
[TBL] [Abstract][Full Text] [Related]
20. Genetic therapy for transplant vascular sclerosis.
Bennett CF; Stepkowski SM
Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
